FOCUS ISSUE: CARDIAC REGENERATION
Safety and Efficacy of Subcutaneous-Only Granulocyte-Macrophage Colony-Stimulating Factor for Collateral Growth Promotion in Patients With Coronary Artery Disease
Stephan Zbinden, MD,
Rainer Zbinden, MD,
Pascal Meier, MD,
Stephan Windecker, MD and
Christian Seiler, MD, FACC, FESC*
Department of Cardiology, University Hospital, Bern, Switzerland
Manuscript received October 20, 2004;
revised manuscript received January 19, 2005,
accepted January 25, 2005.
* Reprint requests and correspondence: Dr. Christian Seiler, Professor and Co-Chairman of Cardiology, University Hospital, CH-3010 Bern, Switzerland. (Email: christian.seiler.cardio{at}insel.ch).
OBJECTIVES: This study was designed to investigate the safety and efficacy of a short-term subcutaneous-only granulocyte-macrophage colony-stimulating factor (GM-CSF) protocol for coronary collateral growth promotion.
BACKGROUND: The safety and efficacy of an exclusively systemic application of GM-CSF in patients with coronary artery disease (CAD) and collateral artery promotion has not been studied so far.
METHODS: In 14 men (age 61 ± 11 years) with chronic stable CAD, the effect of GM-CSF (molgramostim) on quantitatively assessed collateral flow was tested in a randomized, double-blind, placebo-controlled fashion. The study protocol consisted of an invasive collateral flow index (CFI) measurement in a stenotic as well as a normal coronary artery before and after a two-week period with subcutaneous GM-CSF (10 µg/kg; n = 7) or placebo (n = 7). Collateral flow index was determined by simultaneous measurement of mean aortic, distal coronary occlusive, and central venous pressure.
RESULTS: Collateral flow index in all vessels changed from 0.116 ± 0.05 to 0.159 ± 0.07 in the GM-CSF group (p = 0.028) and from 0.166 ± 0.06 to 0.166 ± 0.04 in the placebo group (p = NS). The treatment-induced difference in CFI was +0.042 ± 0.05 in the GM-CSF group and –0.001 ± 0.04 in the placebo group (p = 0.035). Among 11 determined cytokines, chemokines, and their monocytic receptor concentrations, the treatment-induced change in CFI was predicted by the respective change in tumor necrosis factor-alpha concentration. Two of seven patients in the GM-CSF group and none in the placebo group suffered an acute coronary syndrome during the treatment period.
CONCLUSIONS: A subcutaneous-only, short-term protocol of GM-CSF is effective in promoting coronary collateral artery growth among patients with CAD. However, the drug’s safety regarding the occurrence of acute coronary syndrome is questionable.
|
Abbreviations and Acronyms
| | CAD = coronary artery disease | | CFI = collateral flow index | | CVP = central venous pressure | | ECG = electrocardiogram | | GM-CSF = granulocyte-macrophage colony-stimulating factor | | Pao = mean aortic pressure | | Poccl = mean coronary artery occlusive pressure | | PCI = percutaneous coronary intervention | | TNF = tumor necrosis factor |
|
Related Article
-
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor: Double-Edged Swords
- Robert F. Wilson and Timothy D. Henry
J. Am. Coll. Cardiol. 2005 46: 1649-1650.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. Meier, S. Gloekler, S. F. de Marchi, A. Indermuehle, T. Rutz, T. Traupe, H. Steck, R. Vogel, and C. Seiler
Myocardial Salvage Through Coronary Collateral Growth by Granulocyte Colony-Stimulating Factor in Chronic Coronary Artery Disease: A Controlled Randomized Trial
Circulation,
October 6, 2009;
120(14):
1355 - 1363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Meier, J Antonov, R Zbinden, A Kuhn, S Zbinden, S Gloekler, M Delorenzi, R Jaggi, and C Seiler
Non-invasive gene-expression-based detection of well-developed collateral function in individuals with and without coronary artery disease
Heart,
June 1, 2009;
95(11):
900 - 908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Gautier, T. Huby, F. Saint-Charles, B. Ouzilleau, J. Pirault, V. Deswaerte, F. Ginhoux, E. R. Miller, J. L. Witztum, M. J. Chapman, et al.
Conventional Dendritic Cells at the Crossroads Between Immunity and Cholesterol Homeostasis in Atherosclerosis
Circulation,
May 5, 2009;
119(17):
2367 - 2375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen
Stimulation of collateral artery growth: travelling further down the road to clinical application
Heart,
February 1, 2009;
95(3):
191 - 197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer
Insights into mechanisms behind arteriogenesis: what does the future hold?
J. Leukoc. Biol.,
December 1, 2008;
84(6):
1379 - 1391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Cheng, L. Ou, Y. Liu, X. Liu, F. Li, B. Sun, Y. Che, D. Kong, Y. Yu, and G. Steinhoff
Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion
Cardiovasc Res,
December 1, 2008;
80(3):
425 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Grundmann, N. van Royen, G. Pasterkamp, N. Gonzalez, E. J. Tijsma, J. J. Piek, and I. E. Hoefer
A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate Collateral Artery Growth Via Transforming Growth Factor-{beta}1 Release
J. Am. Coll. Cardiol.,
July 24, 2007;
50(4):
351 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-F. Tse and C.-P. Lau
Therapeutic Angiogenesis With Bone Marrow--Derived Stem Cells
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2007;
12(2):
89 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Perera, G. S. Kanaganayagam, M. Saha, R. Rashid, M. S. Marber, and S. R. Redwood
Coronary Collaterals Remain Recruitable After Percutaneous Intervention
Circulation,
April 17, 2007;
115(15):
2015 - 2021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Forrester, M. S. Lee, N. Kapoor, and R. R. Makkar
The Janus Face of Drug-Eluting Stents
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
375 - 376.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kang, H.-Y. Lee, S.-H. Na, S.-A Chang, K.-W. Park, H.-K. Kim, S.-Y. Kim, H.-J. Chang, W. Lee, W. J. Kang, et al.
Differential Effect of Intracoronary Infusion of Mobilized Peripheral Blood Stem Cells by Granulocyte Colony-Stimulating Factor on Left Ventricular Function and Remodeling in Patients With Acute Myocardial Infarction Versus Old Myocardial Infarction: The MAGIC Cell-3-DES Randomized, Controlled Trial
Circulation,
July 4, 2006;
114(1_suppl):
I-145 - I-151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Deindl, M.-M. Zaruba, S. Brunner, B. Huber, U. Mehl, G. Assmann, I. E. Hoefer, J. Mueller-Hoecker, and W.-M. Franz
G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis
FASEB J,
May 1, 2006;
20(7):
956 - 958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1689 - 1706.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Wilson and T. D. Henry
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor: Double-Edged Swords
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1649 - 1650.
[Full Text]
[PDF]
|
|
|
|
